Literature DB >> 27028210

Reduced alloimmunization in mice following repeated transfusion with pathogen-reduced platelets.

Marcus O Muench1,2, John W Heitman1, Heather Inglis1, Marina E Fomin1, Susanne Marschner3, Raymond P Goodrich3, Philip J Norris1,2,4, Rachael P Jackman1,2.   

Abstract

BACKGROUND: Allogeneic transfusion can result in alloimmunization, leading to platelet (PLT) refractoriness and rejection of solid organ transplants. Previously we demonstrated that pathogen reduction using UV light and riboflavin (UV + R) eliminates the immunogenicity of white blood cells (WBCs) in vitro, blocks alloimmunization from transfusion in mice, and results in reduced ex vivo cytokine responses to subsequent untreated transfusions. We sought to determine if repeated transfusion with pathogen-reduced PLT-rich plasma (PRP) would eventually cause breakthrough alloimmunization or enhanced tolerance. STUDY DESIGN AND METHODS: BALB/cJ mice were transfused weekly for 2, 4, or 8 weeks with C57Bl/6J PRP that was either untreated or pathogen reduced with UV + R and leukoreduced or not. Alloimmunization was determined by measuring donor antibody levels, ex vivo cytokine responses, and 24-hour donor PLT recovery. The role of donor antibodies in PLT refractoriness was also assessed by transfer of diluted immune sera into naïve recipients.
RESULTS: Donor antibody levels increased with the number of transfusions, but levels were significantly reduced using either UV + R or leukoreduction, and combining UV + R and leukoreduction gave the best protection. Priming of ex vivo cytokine responses required WBCs and remained suppressed with repeated UV + R-treated transfusion. PLT recovery was reduced with UV + R in naïve mice, and multiply transfused mice had poor PLT recovery even when antibody levels were relatively low. Approximately 1/100 dose of serum from a multiply transfused mouse was sufficient for complete rejection of donor PLTs.
CONCLUSIONS: Pathogen reduction significantly reduces alloimmunization in repeatedly transfused mice and combined with leukoreduction provides a high level of protection from alloimmunization.
© 2016 AABB.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27028210     DOI: 10.1111/trf.13579

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  8 in total

1.  Pathogen-reduced PRP blocks T-cell activation, induces Treg cells, and promotes TGF-β expression by cDCs and monocytes in mice.

Authors:  Johnson Q Tran; Marcus O Muench; Rachael P Jackman
Journal:  Blood Adv       Date:  2020-11-10

2.  Allogeneic major histocompatibility complex antigens are necessary and sufficient for partial tolerance induced by transfusion of pathogen reduced platelets in mice.

Authors:  Johnson Q Tran; Marcus O Muench; John W Heitman; Rachael P Jackman
Journal:  Vox Sang       Date:  2019-02-07       Impact factor: 2.144

3.  Reduced MHC alloimmunization and partial tolerance protection with pathogen reduction of whole blood.

Authors:  Rachael P Jackman; Marcus O Muench; Heather Inglis; John W Heitman; Susanne Marschner; Raymond P Goodrich; Philip J Norris
Journal:  Transfusion       Date:  2016-11-18       Impact factor: 3.157

4.  Haemostatic function measured by thromboelastography and metabolic activity of platelets treated with riboflavin and UV light.

Authors:  Carme Ballester-Servera; Teresa Jimenez-Marco; Daniel Morell-Garcia; Miguel Quetglas-Oliver; Antonia M Bautista-Gili; Enrique Girona-Llobera
Journal:  Blood Transfus       Date:  2020-05-15       Impact factor: 3.443

5.  A small allelic variant in donor class I MHC is sufficient to induce alloantibodies following transfusion of standard or pathogen-reduced platelets in mice.

Authors:  Rachael P Jackman; John W Heitman; Marcus O Muench
Journal:  Vox Sang       Date:  2020-03-23       Impact factor: 2.144

6.  In utero exposure to alloantigens primes alloimmunization to platelet transfusion in mice.

Authors:  Jacqueline N Poston; Arijita Jash; Lindsay M Hannan; Ariel M Hay; Chomkan Usaneerungrueng; Heather L Howie; Linda M Kapp; James C Zimring
Journal:  Transfusion       Date:  2020-12-18       Impact factor: 3.337

7.  Potential of Membranes Surrounding the Fetus as Immunoprotective Cell-Carriers for Allogeneic Transplantations.

Authors:  Padma Priya Togarrati; Nuntana Dinglasan; Elizabeth Yee; John W Heitman; Rachael P Jackman; Mark Geisberg; Philip J Norris; Alicia Bárcena; Marcus O Muench
Journal:  Transplant Direct       Date:  2019-05-29

Review 8.  Transfusion as an Inflammation Hit: Knowns and Unknowns.

Authors:  Olivier Garraud; S Tariket; C Sut; A Haddad; C Aloui; T Chakroun; S Laradi; F Cognasse
Journal:  Front Immunol       Date:  2016-11-29       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.